12
Dec

On the rebound after a dalliance with AbbVie and its $55 billion red herring, Shire CEO Flemming Ornskov is back on the offensive, talking up his company’s potential to rub elbows with the biggest among Big Biotech.

…read more

Source: Shire chief: We want to be like Gilead, Biogen and Celgene

    

0 No comments